ENDRA Life Sciences Inc. (NDRA) Stock Price, Quote & News - Stock Analysis (2024)

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit ENDRA Provides Update Following In-person Meeting with FDA ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024 ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 ENDRA Life Sciences Installs First TAEUS System in the UK New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023 ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023 Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023 ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023 ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023 Study Highlighting ENDRA Life Sciences' TAEUS Technology to be Presented at EASL International Liver Congress 2023 References